| Aug 8 |
Collegium Reports Second Quarter 2024 Financial Results
|
| Aug 7 |
Collegium Pharmaceutical Q2 2024 Earnings Preview
|
| Aug 7 |
Unveiling Collegium Pharmaceutical (COLL) Q2 Outlook: Wall Street Estimates for Key Metrics
|
| Aug 5 |
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
| Aug 1 |
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
|
| Jul 31 |
Collegium Pharmaceutical (COLL) Soars 10.6%: Is Further Upside Left in the Stock?
|
| Jul 30 |
Collegium buys Ironshore for $525m and enter ADHD market
|
| Jul 29 |
Collegium to acquire Ironshore Therapeutics, reaffirms 2024 outlook for current business
|
| Jul 29 |
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
|
| Jul 25 |
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
|
